2.22
+0.03(+1.37%)
Currency In USD
| Previous Close | 2.19 |
| Open | 2.19 |
| Day High | 2.29 |
| Day Low | 2.19 |
| 52-Week High | 3.2 |
| 52-Week Low | 1.26 |
| Volume | 123,060 |
| Average Volume | 200,364 |
| Market Cap | 64.01M |
| PE | -2.88 |
| EPS | -0.77 |
| Moving Average 50 Days | 2.49 |
| Moving Average 200 Days | 2.11 |
| Change | 0.03 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $604.9 as of September 12, 2025 at a share price of $2.22. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $1,283.24 as of September 12, 2025 at a share price of $2.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
GlobeNewswire Inc.
Yesterday at 1:15 PM GMT
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopha
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
GlobeNewswire Inc.
Sep 08, 2025 8:05 PM GMT
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announ
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Aug 25, 2025 1:30 PM GMT
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today anno